Leiden,  The Netherlands,  January 05, 2010.  Biotech  company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has
secured     a     convertible    debt    financing    of    Euro    7.5 million.

The  financing  has  been  structured  in  the  form  of a one year (non-listed)
convertible  debt instrument that  is convertible into  Pharming shares at  Euro
0.50. The  debt has a coupon of 9 per cent  per annum and is subordinated to the
existing   Euro 10.9 million convertible bond.  In addition, 15 million warrants
are  being  issued  to  investors  with  an  exercise  price of  Euro 0.50and an
expiration date of December 31, 2012. Pharming has access to an additional  Euro
2.5 million  under this convertible debt  agreement on mutually acceptable terms
to              investors              and              the             Company.

The  convertible debt can be repaid in cash in whole or in part at the option of
the investor if a commercialisation deal for Rhucin materialises with an upfront
payment  in excess of  an undisclosed amount.  Under specific future conditions,
the  conversion  price  and  exercise  price  of  the  warrants could be reduced
according  to the lowest five day volume weighted average share price along with
a       5% discount       following       a      notice      of      conversion.

Dr.  Sijmen de Vries, Chief Executive Officer of Pharming, said: "This financing
provides a good basis for Pharming to work with the EMEA and FDA to bring Rhucin
forward  through the  regulatory review  process and  also allows the Company to
complete        commercialisation        partnerships        for        Rhucin."

Roth  Capital  Partners,  LLC  acted  as  financial  advisor to Pharming in this
transaction.


About  Pharming Group NVPharming Group NV  is developing innovative products for
the  treatment  of  genetic  disorders,  ageing diseases, specialty products for
surgical  indications, and nutritional products. Pharming's lead product Rhucin®
for acute attacks of Hereditary Angioedema has passed clinical development stage
and  the Market Authorization Application is  under review with EMEA. Prodarsan®
is in early stage clinical development for Cockayne Syndrome and lactoferrin for
use in food products The advanced technologies of the Company include innovative
platforms  for the production of  protein therapeutics, technology and processes
for the purification and formulation of these products, as well as technology in
the  field of DNA repair (via DNage). Additional information is available on the
Pharming     website,     http://www.pharming.com.     <http://www.pharming.com>


This  press release contains  forward looking statements  that involve known and
unknown  risks,  uncertainties  and  other  factors,  which may cause the actual
results,  performance or achievements of the  Company to be materially different
from  the results,  performance or  achievements expressed  or implied  by these
forward                            looking                           statements.

Contact:
Ms. Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6
109 299 54


[HUG#1370273]





    Press release (PDF): http://hugin.info/132866/R/1370273/335143.pdf